We are live on ! Find out more
CODX icon

Co-Diagnostics
CODX

10 hedge funds and large institutions have $827K invested in Co-Diagnostics in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

206% more capital inflows, than outflows

Capital inflows: $73.5K | Capital outflows: $24K

0.24% more ownership

Funds ownership: 5.07% → 5.31% (+0.24%)

0% more funds holding

Funds holding: 10 → 10 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
10
Holders Change
–
Holders Change %
0%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
+$36.9K
2
Renaissance Technologies
Renaissance Technologies
New York
+$15.7K
3
Barclays
Barclays
United Kingdom
+$13.6K
4
Deutsche Bank
Deutsche Bank
Germany
+$5.25K
5
HighTower Advisors
HighTower Advisors
Illinois
+$1.98K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$21K
2
Victory Capital Management
Victory Capital Management
Texas
-$2K
3
UBS Group
UBS Group
Switzerland
-$1K

CODX Hedge Fund Activity: Q4 2019 in Review

10 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q4 2019, worth a combined $827K — down 7.9% from $898K a quarter earlier.

Fund positioning in CODX was balanced in Q4 2019: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $36.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $21K sold.

  • 10 institutional investors held Co-Diagnostics (CODX) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $827K of Co-Diagnostics stock for Q4 2019, down 7.9% quarter-over-quarter.
  • 3 funds opened new Co-Diagnostics positions in Q4 2019 and 3 closed out, a net change of 0 holders.
  • The largest Co-Diagnostics buyer in Q4 2019 was Virtu Financial, an estimated $36.9K added.
  • The largest Co-Diagnostics seller in Q4 2019 was Citadel Advisors, an estimated $21K sold.

Based on aggregated 13F filings for Q4 2019.